A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cyclophosphamide (Primary) ; Sirolimus (Primary) ; Fludarabine; Mycophenolate mofetil
Indications Graft-versus-host disease
Focus Therapeutic Use

15 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
07 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com